Table A1. Distribution of Streptococcus pneumoniae serotypes and antimicrobial susceptibility patterns, Palestinian Territories, West Bank*.
| Serotype | No. (%) isolates | Penicillin, % |
Cefotaxime, % |
Co-trimoxazole, % |
Erythromycin, % |
Ofloxacin, % |
Vancomycin, % |
|||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S | I | R | S | I | R | S | I | R | S | I | R | S | I | R | S | I | R | |||||||
| 6A/B | 17 (14.2) | 100 | 0 | 0 | 100 | 0 | 0 | 52.9 | 11.8 | 35.3 | 47.1 | 5.9 | 47.1 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 14 | 16 (13.3) | 87.5 | 13.5 | 0 | 100 | 0 | 0 | 18.8 | 6.2 | 75 | 25 | 0 | 75 | 87.5 | 12.5 | 0 | 100 | 0 | 0 | |||||
| 1 | 14 (11.7) | 100 | 0 | 0 | 100 | 0 | 0 | 7.14 | 35.7 | 57.1 | 92.9 | 7.1 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 9V | 11 (9.2) | 100 | 0 | 0 | 100 | 0 | 0 | 27.3 | 18.2 | 54.6 | 90.9 | 0 | 9.1 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 5 | 9 (7.5) | 100 | 0 | 0 | 100 | 0 | 0 | 11.1 | 66.7 | 22.2 | 88.9 | 0 | 11.1 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 19F | 8 (6.7) | 100 | 0 | 0 | 100 | 0 | 0 | 37.5 | 12.5 | 50 | 62.5 | 0 | 37.5 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 4 | 6 (5.0) | 100 | 0 | 0 | 100 | 0 | 0 | 83.3 | 0 | 16.7 | 66.7 | 16.7 | 16.7 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 19A | 5 (4.2) | 100 | 0 | 0 | 100 | 0 | 0 | 40 | 20 | 40 | 60 | 20 | 20 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| Sg18 | 5 (4.2) | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 3 | 4 (3.3) | 100 | 0 | 0 | 100 | 0 | 0 | 50 | 0 | 50 | 25 | 25 | 50 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 7F | 4 (3.3) | 100 | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 100 | 50 | 0 | 50 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 8 | 3 (2.5) | 100 | 0 | 0 | 100 | 0 | 0 | 0 | 66.7 | 33.3 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 23F | 3 (2.5) | 100 | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 35B | 3 (2.5) | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 12F | 2 (1.7) | 100 | 0 | 0 | 100 | 0 | 0 | 50 | 50 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 16F | 2 (1.7) | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 33F | 2 (1.7) | 100 | 0 | 0 | 100 | 0 | 0 | 0 | 100 | 100 | 50 | 0 | 50 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 8 | 1 (0.8) | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 17F | 1 (0.8) | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| 38F | 1 (0.8) | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 | |||||
| NT |
3 (2.5) |
100 |
0 |
0 |
|
100 |
0 |
0 |
|
100 |
0 |
0 |
|
100 |
0 |
0 |
|
100 |
0 |
0 |
|
100 |
0 |
0 |
| Total |
120 |
98.3 |
1.7 |
0 |
|
100 |
0 |
0 |
|
38.3 |
17.5 |
44.2 |
|
68.3 |
5 |
26.7 |
|
98.3 |
1.7 |
0 |
|
100 |
0 |
0 |
| *S, susceptible; I, intermediate; R, resistant; NT, not serotyped. Boldface indicates pneumococcal conjugate valent 13 vaccine serotypes. Susceptibility testing and interpretation guidelines: penicillin MIC by Etest (S<2, I: 4, R>8 μg/mL); cefotaxime MIC by Etest (S<1, I 2, R>4 μg/mL); co-trimoxazole disk diffusion (S>19, I 16–18, R<15 mm); erythromycin disk diffusion (S>21, I 16–20, R<15 mm); ofloxacin disk diffusion (S>16, I 13–15, R<12 mm); vancomycin disk diffusion (>17 mm). | ||||||||||||||||||||||||